Genome-Wide Association Studies of Chemotherapeutic Toxicities: Genomics of Inequality.

ABSTRACT: With an estimated global population of cancer survivors exceeding 32 million and growing, there is a heightened awareness of the long-term toxicities resulting from cancer treatments and their impact on quality of life. Unexplained heterogeneity in the persistence and development of toxicities, as well as an incomplete understanding of their mechanisms, have generated a growing need for the identification of predictive pharmacogenomic markers. Early studies addressing this need used a candidate gene approach; however, over the last decade, unbiased and comprehensive genome-wide association studies (GWAS) have provided markers of phenotypic risk and potential targets to explore the mechanistic and regulatory pathways of biological functions associated with chemotherapeutic toxicity. In this

SUBMITTER: Mapes B 

PROVIDER: S-EPMC5540779 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature